Vitamin market: Stability with modest declines across key vitamins
The vitamin market is currently experiencing a period of stability, with some vitamins showing slight declines in price due to varying factors such as supply-demand dynamics and production capacities. While manufacturers continue to push for higher prices, market conditions and contracted agreements for upcoming quarters are keeping the market relatively balanced. Below is an overview of the latest trends in key vitamins, highlighting the current market status and future outlook (week 11).
In partnership with Feed Additive Prices
Vitamin E 50%
The market remains stable to weak as spot availability presents slight discounts. Manufacturers are actively seeking stable to firmer prices though, but without success. Adequate stock levels have contributed to price stability and even allowed for minimal decline. Contracts for the first quarter are secured, with a portion of the second quarter also confirmed.
Vitamin A 1000
The market currently exhibits a stable to weak phase, with a cautious outlook influenced by anticipated increases in production capacity from China and the return of a Western supplier. That Western manufacturer is still expected to return to the market from their force majeure situation in early Q2 2025. Buyer activity remains hesitant and marked by a wait-and-see approach. First-quarter contracts are already in place and some second-quarter agreements are secured as well.
Vitamin D3 500
The current market for Vitamin D3 remains robust as tight spot availability and suppliers’ efforts to maintain elevated prices persist, primarily due to ongoing material shortages. A good portion of Q2 is contracted by now, as buyers do not expect nearby price relief.
Vitamin B2 80%
The market continues to display stability with consistent prices and a positive outlook on availability, bolstered by the recent approval of a new Chinese supplier for the EU market. Although manufacturers remain inclined to pursue price increases, the prevailing stability reflects a balanced market environment. Looking forward, notable fluctuations are not expected in the short-term, with Q1 and the majority of Q2 already fully contracted.
D-Calpan
In all regions, the market remains quite stable regarding actual transaction prices and the market price continues to be low. While some key suppliers of d-calpan are eager to see prices rise, the prevailing oversupply has so far prevented a shift from the current pricing structure, and no significant changes are anticipated in the near future. The first quarter and part of the second quarter are already contracted.
Vitamin B3
Despite the recent incident at a vitamin B3 production facility, market trends continue to show weakness, with prices experiencing a slight decline relative to previous weeks. Supply availability remains strong, and suppliers are actively competing to sustain or increase their market share, while the first quarter and a significant portion of the second quarter have already been contracted.
Biotin
Recently, a small price decline was seen for biotin pure and that has led to a small decline in the diluted biotin 2% product as well. The biotin market has shown stability over the past few months, consistently maintaining a historically low level. The current market remains balanced, with no significant fluctuations expected in the short-term. Contracts for the first quarter are firmly in place, along with a large portion of agreements for the second quarter.
Vitamin C 35% mono
While vitamin C prices remain mostly stable, a slight decline in sentiment is observable in certain regions. Current market trends reveal a strong desire among suppliers to implement price increases either directly or by restricting offers, even as some suppliers are quoting lower FOB China prices compared to previous weeks. This has led to a largely static market with prices remaining steady or slightly decreasing in specific areas, contrary to the anticipated upward movement. Furthermore, a significant number of contracts for both the first and second quarters have already been finalised.
